Overview

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Status:
Not yet recruiting

Trial end date:
2025-04-30

Target enrollment:

Participant gender:

Summary

The main aim of the study is to check side effect from the study treatment with TAK-771 in long term. Participants can have taken part in the previous study TAK-771-3004 (NCT05150340). For those who can take part, the participants will receive injections of TAK-771 after the end of the previous study. The participants will be treated with TAK-771 for totally 3 years. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Immunoglobulins